MarketWatchCenter·
Hims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying.
As part of the agreement, Hims said it won’t compound GLP-1 medications like Zepbound in the future.
Read at MarketWatch →
Markets · 1 sources covering this
Hims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying.
As part of the agreement, Hims said it won’t compound GLP-1 medications like Zepbound in the future.
Coverage spectrum
0 L · 1 C · 0 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/9e380c3592a8e764ea205189e3194d62ff106563" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Hims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying."></iframe>
